Allozymes, which applies its proprietary platform technology to rapidly develop novel enzymes and enable the manufacture of complex natural products, raised $15 million in Series A financing with new investors Seventure Partners, NUS Technology Holdings, Thia Ventures and ID Capital, with repeat investment from Xora Innovation, SOSV, Entrepreneur First and Transpose Platform. Altij advised Allozymes on French aspects of the operation. Counsel in Singapore was Cooley LLP.
Partner Nicholas Cullen (Corporate/IT) led the Altij team advising Allozymes.